However, a phase II clinical trial of thalidomide in ALS patients did not show any differences in disease progression according to the ALS functional Rating Scale Revised (ALSFRS-R), compared to historical controls, and no significant changes in serum levels of TNF-α were determined [124]. This evidence concerns the gene TNF and amyotrophic lateral sclerosis.